---
document_datetime: 2026-01-09 10:12:11
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/harvoni-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: harvoni-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.5596997
conversion_datetime: 2026-01-10 11:01:53.286901
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Harvoni

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                     |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------|
| Variation type IB /  | This was an application for a group of | 09/01/2026                          | N/A                                         |                                  | To update the RMP by removing the 'Specific |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000311080   | variations. C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.a Implementation of wording agreed by the competent authority - Accepted C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (Type IB) - To update the RMP by removing the 'Specific Adverse Reaction Follow up Questionnaires' (i.e. targeted questionnaires) for Bradyarrhythmia. C.I.11.a (Type IA_IN) - To update the RMP by removing the following Important Identified Risks (IIRs), both requested by PRAC during the last Harvoni Periodic Safety Update Report (PSUR) procedure EMA/PSUR/0000248480: (1) 'Severe bradycardia and heart block when used with concomitant amiodarone' and (2) 'HBV reactivation in HBV/HCV coinfected patients'. In addition, the MAH took the opportunity to update the post-authorisation exposure data (Section SV.1.2).   | Adverse Reaction Follow up Questionnaires' (i.e. targeted questionnaires) for Bradyarrhythmia. To update the RMP by removing the following Important Identified Risks (IIRs), both requested by PRAC during the last Harvoni Periodic Safety Update Report (PSUR) procedure EMA/PSUR/0000248480: (1) 'Severe bradycardia and heart block when used with concomitant amiodarone' and (2) 'HBV reactivation in HBV/HCV coinfected patients'. In addition, the MAH took the opportunity to update the post-authorisation exposure data (Section SV.1.2).   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| PSUR / EMA/PSUR/0000248480   | - -   | Based on the PRAC review of data on safety and efficacy, the PRAC considers that the benefit-risk balance of medicinal products containing sofosbuvir / ledipasvir remains unchanged and therefore recommends the maintenance of the marketing authorisation(s).   |
|------------------------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|